Hearts & Minds Blog

Looking Back on a Successful 2013 and a Glance Ahead at a Promising 2014

Tim Mayleben

President and Chief Executive Officer

Esperion had an incredible year in 2013 with more successes, both clinically and financially, than in any other year since we were founded in April 2008 as the new Esperion. We executed on all of our milestones – all toward our goal of bringing ETC-1002 to market. A unique, first-in-class, oral, once-daily investigational small molecule, ETC-1002 is designed to lower levels of low-density lipoprotein cholesterol (LDL-C) and avoid the side effects associated with existing LDL-C lowering therapies. Our goal is to develop ETC-1002 for the… more

Why we Like the New AHA/ACC Cholesterol Guidelines

Tim Mayleben

President and Chief Executive Officer

On November 12, the American College of Cardiology (ACC) and the American Heart Association (AHA) released new guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease (ASCVD) risk in adults. These guidelines represent an important shift from past cholesterol guidelines and are of particular interest to Esperion because we are working to develop ETC-1002. This unique, first-in-class, oral, once-daily investigational small molecule is designed to lower levels of low-density lipoprotein cholesterol (LDL-C) and avoid the side effects associated with existing LDL-C lowering… more

Working to Impact the Lives of Millions of Statin Intolerant Patients

Tim Mayleben

President and Chief Executive Officer

I re-joined Roger at Esperion almost a year ago to help people who are at risk for debilitating and life-threatening heart attacks and strokes because they have elevated levels of LDL-C (the bad cholesterol), but who are unable to take a statin because of myalgia (muscle pain). These patients are considered statin intolerant – and there are an estimated 2 million of them in the United States. While statins are the cornerstone of lipid treatment today and are highly effective at lowering LDL-C, many patients… more

The Coming Revolution in LDL-Cholesterol Lowering

Marianne Andreach

Senior Vice President, Strategic Marketing and Product Planning

I have spent close to 30 years working in the cardio-metabolic area in the pharmaceutical industry with products such as Pravachol®, Lipitor®, Glucophage®, Plavix® and ApoA-I Milano (ETC-216). My roles have been as varied as lab scientist, salesperson, marketer, educator and now vice president of strategic marketing and product planning for Esperion. Looking back reminds me of how far we have come. Even as late as the early 1990s, we were still educating physicians about high cholesterol as a risk factor, as well as the… more

The Promise of ETC-1002 for Patients at Risk of Cardiovascular Disease

Noah Rosenberg

Chief Medical Officer

Many years ago, as an attending physician in an academic emergency department, I was surprised to see a number of patients presenting with advanced cardiovascular disease (CVD). What made this so unusual was that these patients had no known “traditional” CVD risk factors, such as smoking or high blood pressure, but were all relatively young–in their 30s or 40s–and obese. Their CVD had progressed beyond our ability to reverse years of damage. Oftentimes, I felt helpless and wanted to do something to help prevent people… more